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 HIV infection, and tobacco smoking, two areas of major health concern which 
continue to grow worldwide, both of which have detrimental health effects on the 
population. The point of intersection where these two health concerns cross is the focus 
of this study.  
 Here, a possible link between HIV infectivity levels and tobacco smoking at the 
point of cellular gene expression differences seen in the presence of tobacco smoke is 
described. This research presents evidence of increased HIV infectivity in the presence of 
tobacco smoke. qRT-PCR analysis is used to confirm micro array gene expression 
results. Twelve genes were identified to be overexpressed or under-expressed as a result 
of exposure to tobacco smoke extract (TSE). The expression of those twelve genes was 
then knocked down individually using siRNA technology in T-cells. HIV infectivity 
levels were then measured using a novel luciferase assay system in those cell lines which 
were under expressing the gene of interest. Dual gene knockdown cell lines were also 
used in the study. 
 The results show that in the eight genes whose expression is up regulated as a 
result of TSE (which could be increasing HIV infectivity), upon the knockdown in 
expression of those genes, six of the eight show a significant decrease in HIV infectivity 
in T-cells. In the four genes whose expression is down regulated as a result of TSE 
(which could be increasing HIV infectivity), after the knockdown in expression of those 
genes, three of the four show a significant increase in HIV infectivity in T-cells. 
Together, these results shed light on the specific genes whose expression is altered due to 
TSE and how these gene regulation changes may affect HIV viral infectivity levels.   
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CHAPTER I 
 
INTRODUCTION 
 
 
HIV and Smoking 
 
Tobacco smoking and HIV/AIDS are the only two international major causes of 
death that continue to grow [1]. Where these two factors cross should present a major 
area of public health concern. Cigarette smoking has many negative biological effects on 
the body, but for those individuals who are exposed to HIV it may be especially harmful. 
Smoking is known to increase the risk of various types of cancers, decrease the ability of 
the body to heal wounds, cause oral and gum diseases, and chronic inflammatory disease 
of the lungs leading to decreased lung function. With chronic inflammation of the lungs 
comes emphysema and bronchitis, which can lead to smoker’s leukocytosis, which is the 
body’s immune response by increasing the white blood cell count.  A study by the United 
States Food and Drug Administration indicated that constituents of cigarette smoke may 
induce HIV production in chronically infected cells [2]. Individuals infected with HIV 
are about three times more likely to smoke than those who are not, and HIV infection is 
more common among smokers than non-smokers. HIV infected war veterans who 
currently smoke have a decreased quality of life, an increase in mortality, chronic 
obstructive pulmonary disease, and bacterial pneumonia compared to non-smoking HIV 
infected war veterans [3].  
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Background 
 Previous clinical studies measuring the relevance of tobacco smoking on HIV 
seroconversion (detectable amounts of anti-HIV antibodies in the blood serum) indicate 
that tobacco smoking is associated with an increased risk of acquiring HIV infection. 
Briefly, Siraprapasiri et. al. did a cross sectional study of men attending a sexually 
transmitted diseases clinic located in Chiang Mai, Thailand. 124 HIV negative and 26 
HIV positive men were included in the study where they used a multivariate analysis, 
concluding that smoking was associated with HIV seropositivity (95% CI = 1.2 – 10.5) 
[4]. Burns et. al. looked at the seroconversion rate of 202 homosexual men enrolled with 
three primary care physicians in Washington D.C. and New York over a period of 6 years 
(1982-1988).  The study included those found to be anti-HIV antibody positive at the 
time of enrollment (n=84), those who seroconverted during the observation period 
(n=47), and those who stayed anti-HIV antibody negative at the end of the study (n=71). 
The researchers found that those who were initially anti-HIV antibody negative were 
more likely to seroconvert if they smoked (p=0.03), the study also found that there was 
no difference between smoking status and the progression to AIDS (p=0.31) [5]. Studies 
looking at the association of tobacco smoking and the progression to AIDS show a 
different outcome. Nine published studies were found that tested whether smoking 
increased the time it took patients to progress to AIDS [5-13]. However, most of these 
studies were done over a short period of time in more developed countries, and were 
performed before the use of antiretroviral therapies were the standard care in these cases.  
Due to this it may be the case that smoking does not have an effect in the development of 
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AIDS, which may be because the immune mechanisms that smoking alters are more 
relevant in acquiring HIV infection rather than in the progression to AIDS [14].  
 Since the first use of Highly Active Anti-Retroviral Therapy (HAART) in 1996, 
studies have shown a 60%-80% decrease in new AIDS illnesses. This type of aggressive 
treatment is used to suppress the replication of HIV, and therefore the progression of the 
disease.  HAART therapy uses a combination of three different drugs, of which can 
include Protease Inhibitors (PI), Nucleoside Reverse Transcriptase Inhibitors (NRTI’s), 
and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI’s).   
Protease inhibitors prevent viral replication by inhibiting the activity of HIV-1 
protease which is essential in the life cycle of the virus. HIV-1 protease cleaves viral 
polyproteins to make mature viral proteins needed to form a fully infectious HIV virion. 
Protease inhibitors are peptidomimetic and contain a non-scissile hydroxyethylene bond 
(-CH2-CHOH-) rather than a normal hydrolysable peptide bond (-CO-NH-), and bind in 
the active pocket of the HIV-1 protease enzyme which will inactivate them preventing 
cleavage of the HIV polyproteins.  When the HIV-1 protease is stopped the virions are 
unable to replicate and infect more cells.  
Nucleoside reverse transcriptase inhibitors are competitive inhibitors and work by 
introducing faulty versions of nucleotides that the reverse transcriptase of HIV uses in the 
conversion of viral RNA into DNA. There are 3 phosphorylation steps that convert the 
2’3’-dideoxynucleoside into its 5’-triphosphate derivative.  Due to the absence of the 5’-
OH group in NRTI’s when it is incorporated into the forming DNA strand it will act as a 
chain terminator in the reverse transcription reaction.  
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Non-Nucleoside Reverse Transcriptase Inhibitors act as a non-competitive 
inhibitor of reverse transcriptase. This class of drugs allosterically binds a hydrophobic 
pocket of the enzyme close to the catalytic site causing a conformational change in the 
structure of the enzyme. The binding of the NNRTI affects the catalytic activity and 
blocks HIV-1 replication by inhibiting the ability of the reverse transcriptase to transcribe 
the viral RNA.  When the NNRTI binds the hydrophobic pocket, it causes the p66 
domain to become hyper extended due to the rotamer conformation of amino acid 
residues Tyr-181, and Tyr-188 [15].  
HAART can be very effective in the treatment of HIV and has even been proven 
to reduce the amount of active virus so it is undetectable by blood testing techniques.  
However, some of the benefits provided by HAART can be severely decreased in those 
who smoke. Feldman et. al. assessed the association of cigarette smoking with the 
effectiveness of HAART in low income women. The study included 400 women who 
were nonsmokers and 524 women who smoke cigarettes all of which were on an HAART 
regimen, and lasted up to 7.9 years.  The study looked at seven variables in HAART 
women who were smokers or nonsmokers.  The variables were viral response (HIV-1 
RNA levels dropped to <80 copies/ml), viral rebound (HIV-1 RNA increased to >1000 
copies/ml after initial viral response), immunologic response (time for CD4+ lymphocyte 
counts to increase by 100 cells beyond pre-HAART levels), immunologic failure (CD4+ 
lymphocyte counts dropped below pre-HAART levels), AIDS incidence, total deaths, and 
death from AIDS. The results indicated that smokers using HAART had poorer viral 
responses, poorer immunologic responses, a greater risk of viral rebound, and more 
5 
 
frequent immunologic failure than nonsmokers on HAART.  Smokers on HAART also 
had a higher risk of death and higher risk of developing AIDS than nonsmokers on 
HAART.  In fact only one variable, risk of death due to AIDS, had no significant 
difference between smokers and nonsmokers [16]. The data suggests that treatment of 
HIV positive individuals with HAART will be less effective in those who smoke 
cigarettes than those who do not. 
 In trying to determine the biochemical association between tobacco smoking and 
the increase in HIV infectivity, most of the research has focused on epidemiological 
studies rather than the molecular interactions between the two.  In order to rectify this, 
this this research was aimed at filling this gap by studying the interactions between 
tobacco smoke and HIV infection at a cellular and genetic level. 
Preliminary studies show that an aqueous tobacco smoke extract (TSE) used at 
nicotine concentrations consistent with plasma nicotine concentrations found in smokers, 
can enhance HIV infectivity.  Although, nicotine alone has no effect on HIV infectivity at 
this concentration level.  The studies that will be proposed here will explore the 
ramifications of the discovery that water soluble components of tobacco smoke, other 
than nicotine, are able to induce up to 100% increase in the level of HIV production by T-
cells in vitro. The proposal will try to deduce the cellular genes and mechanisms behind 
this increase in HIV production. This could potentially reveal a novel viral activation 
mechanism, for which inhibitors could be discovered, leading to a new way to possibly 
inhibit the spread of HIV. 
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In order to elucidate the cellular genes, pathways, and biochemical mechanisms 
involved in HIV stimulation by TSE, the specific aims were to: 
1. Use micro arrays to assess the effect of tobacco smoke extract on the genetic 
expression profile of Human T-cells. 
2. Confirm results using quantitative real-time PCR analysis of the expression of 
specific genes that were identified by the micro array. 
3. For the genes that are up-regulated as a result of tobacco smoke extract, siRNA 
will be used to silence the expression of that particular gene in human T-cell’s.  If 
the knockdown of this gene causes a decrease in HIV production, this would 
indicate a role for that gene in the stimulation of HIV infectivity resulting from 
overexpression due to the tobacco smoke extract. 
4. For the genes that are down-regulated as a result of tobacco smoke extract, siRNA 
will be used to silence the expression of that particular gene. If the knockdown in 
expression of that gene in turn mimics the effect seen with the tobacco smoke 
extract, by leading to an increase in HIV production, this would indicate a role for 
that gene in the stimulation of HIV infectivity by tobacco smoke extract. 
5. In order to determine if there is a combinatorial effect caused by gene expression 
levels on HIV production, siRNA will be used to knockdown the expression of 
two genes simultaneously in human T-cells. HIV production levels will then be 
compared to the levels in cells with only a single gene altered.  
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CHAPTER II 
PRELIMINARY STUDIES 
Preparation of Aqueous Tobacco Smoke Extract (TSE) 
 A side arm 125ml Erlenmeyer flask was used and 40ml sterile PBS at room 
temperature was added to the flask. A 10ml pipette was inserted into a rubber stopper 
which capped the flask so that the end of the pipette was submerged into the PBS. 5 
Natural American Spirit cigarettes (Blue Pack: Full-Bodied Taste, manufactured by Santa 
Fe Natural Tobacco Company) were inserted into the end of the pipette with the filter still 
attached. The purpose for using American Spirit cigarettes is to rule out the possibility of 
a chemical additive from certain cigarettes as the constituent that enhances HIV 
infectivity.  American Spirit cigarettes are all natural and are made with no additives in 
the production process. The cigarette was lit and vacuum was applied to the side arm, 
pulling the cigarette smoke through the PBS.  The nicotine concentration in the TSE 
using this method was 100M, measured by the bromination of nicotine method [17].  
This TSE solution will be used throughout all of the studies.  When diluted 100-fold in 
culture media (10l in 1ml) it gives a working nicotine concentration of 1M.  Plasma 
nicotine levels of smokers measured one hour after smoking average around 0.1M, with 
some individuals being as high as 0.25M[18].  This solution can be refrigerated for a  
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couple months and it does not lose any of its potency or the ability to stimulate HIV 
replication. 
 
Use of TMZ-bl (JC53) Cell Line as Quantitative Comparison of Viral Titer 
 The TZM-bl cell line is from the NIH AIDS Research and Reference Reagent 
Program (Catalog #8129) and is used to measure HIV replication levels. The TZM-bl line 
comes from the JC53 Hela cervical cancer cell line, which has been engineered to express 
the CD4 HIV receptor and the CCR5 HIV co-receptor so that it can be infected by the 
virus (JC53-bl).  Then the cell line was further modified by introducing separate 
integrated copies of the luciferase and b-galactosidase genes, which are controlled by the 
HIV-1 long terminal repeat (LTR) promoter/enhancer.  The TZM-bl cell line is readily 
infected by HIV and produces luciferase in proportion to the amount of replicating HIV. 
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Figure 1. Standard Curve for Luciferase Activity Based on Concentration of HIV 
Added. Increasing the dose of viral stock solution increases luciferase production in a 
linear direction, indicating the usefulness of this assay in measuring  HIV replication. 
 
TSE Does Not Activate HIV LTR Signaling 
 In order to use the TZM-bl cell line as an effective measurement of viral titers as a 
result of incubation with TSE, it needed to be determined if TSE alone will activate the 
HIV LTR enhancer region. The expression vector pHIV-lacZ (NIH AIDS Research and 
Reference Reagent program Catalog #151) was used to construct a vector which had four 
copies of the NF-B site in the HIV LTR region. Hela cells were plated in a 24-well plate 
at a concentration of 8.0x10
4
 cells/well and were transfected with the vector and pGL-2 
(a transfection efficiency control) and treated with PBS, TSE (2l/1ml cells), or TNF-
used as a positive control.  
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Figure 2. TSE Does Not Activate the HIV LTR. Activation of the HIV LTR by the 
negative control (PBS) and TSE are the same, indicating that TSE dose not cause 
activation of the HIV LTR. The positive control (TNF-) shows activation due to the 
four copies of the NF-B site in the HIV LTR of the expression vector transfected into 
the cells. 
 
Nicotine Ruled Out as the Constituent Responsible for the Enhancement of 
HIV Infectivity  
 Previous research has shown that nicotine can stimulate the production of HIV by 
in vitro infected alveolar macrophages [19], and the pretreatment of microglia with 
nicotine (300M) would also stimulate HIV production [20]. However, nicotine 
concentrations at the level tested (300M), would not be found in the plasma of living 
humans which have a maximum nicotine concentration of 0.25M an hour after smoking. 
To this end the HIV infectivity enhancement of nicotine at normal levels was tested.  
TZM-bl cells were plated onto a 96-well plate at a concentration of 1.2x10
4
 cells/well, the 
cells were then incubated with increasing doses of TSE (0.075l-2.5l/100l cells), or 
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increasing concentrations of nicotine alone 0.075M-2.5M. The cells were then infected 
with HIV-1 (MOI=0.1). 48 hours post infection, the luciferase activity was measured. At 
doses of TSE as low as 0.15lTSE/100l cells there is an increase in HIV infectivity, 
which nicotine alone shows no increase at normal human plasma concentrations. 
 
 
 
Figure 3. Nicotine Alone is Not Responsible for the Stimulation of HIV Infectivity 
As Seen when Treated with TSE. TZM-bl luciferase activity was measured to 
determine if nicotine alone increased HIV infectivity. It should be noted that because the 
measured concentration of nicotine in TSE is 100uM, 1uL of TSE added to 100uL media 
is a 100-fold dilution, thus equivalent to 1uM nicotine. 
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CHAPTER III 
CELL TOXICITY OF TSE 
Use of MTT Assay to Measure Cell Proliferation 
 Cells are plated on a 96-well plate at a concentration of 1.2x10
4
 cells/well and 
incubated at 37 deg. C and 5% CO2.  After 48 hours 20l of MTT reagent (Thiazolyl 
Blue Tetrazolium Bromide) is added to each well.  The plate is placed on a shaking table 
at 150 rpm’s for 5 minutes to ensure mixing of MTT into the media. The plate is then 
incubated at 37 deg. C, 5% CO2 for 3-4 hours to allow MTT to be metabolized by the 
cells. After incubation the metabolic product of MTT, formazan, produced by the living 
cells will have formed and appear as dark purple crystals in the bottom of the plate. 200l 
of DMSO is added to each of the wells and placed on the shaking table at 150 rpm’s for 5 
minutes in order to dissolve the crystals. The plates are then wrapped in foil and placed in 
a dark room at room temperature for 6 hours. The plates are then read on a micro plate 
reader with the optical density at 450nm measured and the background of 550nm 
subtracted from the reading.  
 
Toxicity of TSE on TZM-bl Cells 
 TZM-bl cells were plated on a 96-well plate at a concentration of 1.2x10
4
 
cells/well and incubated at differing concentrations of TSE that range from 0.15l-10l  
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per 200l growth media. Forty-eight hours after incubation, cell proliferation was 
measured using the MTT method. At about 1l TSE/200l cells there was a ~ 20% 
increase in proliferation. At 5l TSE/200l cells and above there is an anti-proliferative 
effect.  The data shown is from three separate experiments which all show similar results.  
Based on this, no more than a 100 fold dilution 2lTSE/200l cells will be used in the 
experiments to stimulate HIV production. 
 
 
Figure 4. Effect of TSE on Cell Proliferation Using TZM-bl Cells. TSE shows an 
increase in cell proliferation at 2.25lTSE/200l cells and less. Below 5lTSE/200l 
cells there is a decrease in proliferation due to the toxicity of the TSE. 
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Use of Calcein AM and EthD-1 to Measure Cell Viability in the Presence of 
TSE 
Calcein acetoxymethyl ester (Calcein AM) is a hydrophilic compound that easily 
permeates intact live cells and is non-fluorescent. Upon permeating a live cell it is 
hydrolyzed by intercellular esterases turning it into Calcein, a strongly fluorescent, 
hydrophilic compound that is well retained in the cell cytoplasm and not influenced by 
cellular pH [21,22]. Calcein AM was used to measure toxicity levels in Jurkat cells at 
different concentrations of TSE. 
 
Ethidium homodimer-1(EthD-1) is a weakly fluorescent compound that enters 
cells with a damaged membrane and upon binding to nucleic acids becomes highly 
fluorescent. EthD-1 cannot enter intact cells through the plasma membrane thereby 
causing no fluorescent signal in living cells. EthD-1 was used to measure the dead or 
dying Jurkat cells as a result of different concentrations of TSE.  
 
Toxicity of TSE on Jurkat Cells 
Jurkat cells were mixed with 1xPBS at a concentration of 1.0x10
6
 cells/ml, then 
50ul of cell solution was added to a 96well plate (5.0x10
4
 cells/well). TSE solution was 
added to wells in the following amounts, 0.1ul, 0.2ul, 0.3ul, 0.4ul, 0.5ul, 1.0ul, 1.5ul, 
2.0ul, 2.5ul, and no TSE was used as the positive control. 70% EtOH was added as a 
negative control. The plates were then incubated for 6 hours at 37
o
C and 5.0% CO2. Dye 
solutions were prepared according to manufactures recommendations, 2uM Calcein AM, 
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and 4uM EthD-1 both diluted in 1xPBS. Following the 6 hour cell incubation 50ul of the 
diluted dye solution was added to each well. Fluorescence was measured using the Biotek 
fluorescence microplate reader. Calcein was measured at ex322nm/em435nm, and EthD-
1 measured at ex528nm/em617nm. 
 
 
Figure 5. Calcein Fluoresce Levels in Jurkat Cells with Increasing Concentrations of 
TSE 
Jurkat cell viability was measured using Calcein AM with increasing concentrations of 
TSE. TSE dilutions above 0.5ul/50ul cells (100 fold TSE dilution) cause a steady 
decrease in the number of live cells in the sample as seen by the decrease in Calcein 
fluorescence.  
 
 
 
0
10000
20000
30000
40000
50000
60000
No TSE 0.1ul 0.2ul 0.3ul 0.4ul 0.5ul 1.0ul 1.5ul 2.0ul 2.5ul 70%
EtOH
TSE/50ul cells 
Calcein AM (Live Cells) 
16 
 
 
Figure 6. Ethidium Homodimer-1(EthD-1) Fluoresence with Increasing 
Concentrations of TSE. 
EthD-1 becomes highly fluorescent when bound to nucleic acids once inside dead or 
dying cells with compromised cell membranes. At concentrations above 0.5ulTSE/50ul 
cells (100 fold TSE dilution) there is a steady increase in the number of dead Jurkat cells 
as seen by the increase in EthD-1 fluoresence. 
 
 
  The Calcein AM assay indicates a decrease in live Jurkat cells at TSE 
concentrations of 1.0ul TSE/50ul cells and greater. The EthD-1 assay shows an increase 
in the number of dead Jurkat cells at TSE concentrations of 1.0ulTSE/50ul cells and 
greater. Based on this, similar to the TZM-bl cells, no more than a 100-fold dilution of 
TSE will be used in the stimulation of HIV production in Jurkat cells. 
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CHAPTER IV 
EFFECT OF TSE ON HIV INFECTIVITY 
Enhancement of HIV Infectivity by TSE in TZM-bl Cells 
 TZM-bl cells were plated in a 96-well plate at a concentration of 1.2x10
4
 
cells/well and incubated with increasing concentrations of TSE (0.15l-10lTSE/200l 
cells).  The cells were then infected with HIV-1, multiplicity of infection - MOI= 0.1 (1 
infectious viral particle per 10 cells). 48 hours post infection, luciferase activity was 
measured. The results show the % HIV infectivity enhancement based on the amount of 
TSE added to each well. There is an increase in HIV infectivity up to a concentration of 
5lTSE/200l cells, with the highest value exceeding 100% increase at 2.5lTSE/200l 
cells. Beyond 5lTSE/200l cells there is a decline due to the cellular toxicity effect of 
the TSE on the TZM-bl cells. The data is the average of three separate experiments. 
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Figure 7. HIV Infectivity Enhancement Control Based on the Concentration of TSE 
Added to Each Well.  TSE concentrations from 0.15l-10lTSE/200l cells were used. 
TZM-bl luciferase values were measured and reported as % enhancement over control. 
The % enhancement decline beyond 5lTSE/200l cells is due to the cellular toxicity of 
the TSE on the TZM-bl cells. 
 
 
Enhancement of HIV Infectivity by TSE in Jurkat T-cells 
 Human T-cells (Jurkat) were plated on a 24-well plate at a concentration of 
1.0x10
6
 cells/well, then were infected with HIV-1 (MOI=0.1).  The cells were then 
treated with TSE (2l/200l cells), or sterile PBS (2l/200l cells) as a control. 48 hours 
post infection 100l of culture supernatant was added to TZM-bl cells to test for relative 
viral titers.  Luciferase activity from TZM-bl cells was measured and HIV production in 
the T-cells treated with TSE was increased by 51% compared to T-cells treated with PBS. 
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Figure 8. HIV Stimulation in Human T-cells Treated with TSE or PBS (control). 
TZM-bl luciferase activity was measured following the addition of 100l of supernatants 
from Jurkat cell cultures treated with TSE or PBS following HIV infection. Cells treated 
with TSE show a 51% increase in HIV production over cells treated with PBS as 
measured by luciferase activity. 
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CHAPTER V 
 
TSE INDUCED GENE EXPRESSION PATTERNS 
 
 
Regulation of Cellular Gene Expression by TSE 
 
 Since human T-cells are the primary target of HIV, the gene expression profile 
from Jurkat cells was used instead of other cell types.  Jurkat cells were treated with TSE 
or sterile PBS overnight, and then total cellular RNA was extracted and purified using the 
RNeasy Kit (Qiagen Valencia, CA). The samples were sent to the MicroArray Core at 
Wake Forest University, Winston-Salem, NC and run on an Affymetrix HG-U133 Plus 
2.0 chips.  The results showed that TSE affected the expression of more than 12 genes 
(mRNA) based on what was seen with the control PBS RNA. In order to narrow down 
the results, 12 genes were chosen that were all altered by more than 3 times that of the 
control set. Table 1 list the genes that were most significantly up-regulated by TSE.  
Table 2 list the genes that were most significantly down-regulated by TSE. Therefore, 
these are the 12 genes that will be focused on in the following studies. 
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Table 1. Up-Regulated Genes 
 
Up-regulated Genes     
    NCBI GenBank 
Gene Name Gene Function Accession Number 
TAX1BP1 Indirectly binds with viral LTR NM_006024 
CD59, Protectin 
Incorporates into newly formed HIV 
particles and protects  NM_000611 
  
the virus from compliment mediated 
destruction    
Coatomer Protein 
Complex -2 
Essential for Golgi budding and vesicular 
trafficking NM_004766 
Thioredoxin-Related 
an adaptor protein involved in clathrin-
mediated  NM_030755 
 Transmembrane Protein 
1 
endocytosis and HIV-mediated down-
regulation of CD4   
Calmodulin 1 
Binds HIV gp160 and mediates gp160-
enhanced apoptosis NM_006888 
HSP90 beta 1 
Responsible for P-TEFb-mediated Tat 
transactivation NM_003299 
Sjogren Syndrome 
Antigen B Enhances HCV replication NM_003142 
DDX3 Required for HCV replication NM_001356 
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Table 2. Down-Regulated Genes 
 
Down-regulated 
Genes     
    NCBI GenBank 
Gene Name Gene Function  Accession Number 
PHGPx 
Over-expression of PHGPx will inhibit NF-B 
activation NM_002085 
MHC, HLA-E 
Antigen presentation to NK cells. Down 
regulation will  NM_005516 
  
protect virus from MHC 1 cytotoxic T-
lymphocytes   
Stearoyl-CoA 
Desaturase Required for the assembly of VLDL particles AA_678241 
Thioredoxin 
Interacting Protein Binds and inhibits activity of thioredoxin NM_006472 
 
 
qRT-PCR Analysis of Gene Expression  
Jurkat cells were plated on a 24well plate at a concentration of 1.0x10
6
 cells/ml, 
1ml of cells were added to each well along with 10ul TSE solution (100 fold dilution). 
Cells were then placed in an incubator at 37
o
C and 5% CO2. Cells were collected at the 
following time points following incubation, 0 hour, 3 hours, 7 hours, 24 hours, 48 hours, 
and 72 hours. Upon collection, cells were pelleted and stored at -80
o
C. Cell pellets were 
then thawed and mRNA isolation was performed using Sigma GenElute Direct mRNA 
isolation kit (appendix). RNA samples were then quantified and all samples diluted to 
100ng/ul. mRNA samples (200ng) were run through one reverse transcriptase cycle using 
random hexamers in preparation for real time PCR analysis. RT-PCR reaction was setup 
using manufactures recommendations (appendix). Sigma SYBR Green Jumpstart Taq 
was used along with appropriate primer set for each gene. The ∆∆Ct method was 
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performed using the ABI 7500 Fast PCR system, and β-actin was used as an endogenous 
control. GADPH expression was also measured as a positive control. Negative controls 
containing no RT sample were also performed in tandem. Zero hour fluorescence reading 
was normalized to 1 on relative quantitation scale. 
The RT-PCR cycle used was as follows:  
 
95
o
C x 120secs 
95
o
C x 15secs 
55
o
C x 60secs          50x  
Fluorescence read     
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Figure 9. TAX1 Binding Protein 1 RNA Expression in Jurkat Cells after 1% TSE 
Incubation. 
Seven hours post 1% TSE incubation in Jurkat cells, the expression of TAX1BP1 starts to 
increase up to a maximum of 1.87x (at the 72 hour time point) that of the expression 
levels without TSE. 
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Figure 10. CD59 (Protectin) RNA Expression in Jurkat Cells after 1% TSE 
Incubation. 
There is an increase in the expression of CD59 RNA following the incubation with TSE, 
the highest expression levels were seen at the 72 hour time point with levels of 1.90x 
greater than Jurkat expression without TSE. 
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Figure 11. Coatomer Protein Complex β-2 RNA Expression in Jurkat Cells after 1% 
TSE Incubation. 
There is an increase in the expression of coatomer protein complex β-2 RNA following 
the incubation with TSE, the highest expression levels were seen at the 72 hour time 
point with levels of 1.97x greater than Jurkat expression without TSE. 
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Figure 12. Thioredoxin-related Transmembrane Protein 1 RNA Expression in 
Jurkat Cells after 1% TSE Incubation. 
There is an increase in the expression of thioredoxin-related transmembrane protein 1 
RNA following the incubation with TSE, the highest expression levels were seen at the 
12 hour time point with levels of 1.36x greater than Jurkat expression without TSE. 
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Figure 13. Calmodulin 1 RNA Expression Levels in Jurkat Cells after 1% TSE 
Incubation. 
There is an increase in the expression of calmodulin 1 RNA following the incubation 
with TSE, the highest expression levels were seen at the 72 hour time point with levels of 
1.78x greater than Jurkat expression without TSE. 
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Figure 14. Heat Shock Protein 90 β-1 RNA Expression Levels in Jurkat Cells after 
1% TSE Incubation. 
There is an increase in the expression of HSP90 β-1 RNA following the incubation with 
TSE, the highest expression levels were seen at the 12 hour time point with levels of 
1.97x greater than Jurkat expression without TSE. 
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Figure 15. Sjogren Syndrome Antigen B RNA Expression Levels in Jurkat Cells 
after 1% TSE Incubation. 
There is a slight increase in the expression of sjogren syndrome antigen B RNA 
following the incubation with TSE, the highest expression levels were seen at the 48 hour 
time point with levels of 1.13x greater than Jurkat expression without TSE. 
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Figure 16. DEAD Box RNA Helicase 3 RNA Expression Levels in Jurkat Cells after 
1% TSE Incubation. 
There is an increase in the expression of DDX3 RNA following the incubation with TSE, 
the highest expression levels were seen at the 72 hour time point with levels of 2.13x 
greater than Jurkat expression without TSE. 
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Figure 17. Phospholipid Hydroperoxide Glutathione Peroxidase RNA Expression 
Levels in Jurkat Cells after 1% TSE Incubation. 
There is a decrease in the expression of PHGPx RNA following the incubation with TSE, 
the lowest expression levels were seen at the 72 hour time point with levels of 7% that of 
Jurkat expression without TSE. 
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Figure 18. Human Leukocyte Antigen E RNA Expression Levels in Jurkat Cells 
after 1% TSE Incubation. 
There is a decrease in the expression of HLA-E RNA following the incubation with TSE, 
the lowest expression levels were seen at the 12 hour time point with levels of 54% that 
of Jurkat expression without TSE. 
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Figure 19. Stearoyl-CoA Desaturase RNA Expression Levels in Jurkat Cells after 
1% TSE Incubation. 
There is a decrease in the expression of stearoyl-CoA desaturase RNA following the 
incubation with TSE, the lowest expression levels were seen at the 24 hour time point 
with levels of 45% that of Jurkat expression without TSE. 
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Figure 20. Thioredoxin Interacting Protein RNA Expression Levels in Jurkat Cells 
after 1% TSE Incubation. 
There is an overall decrease in the expression of thioredoxin interacting protein RNA 
following the incubation with TSE, the lowest expression levels were seen at the 72 hour 
time point with levels of 90% that of Jurkat expression without TSE. 
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Figure 21. Glyceraldehyde 3-Phosphate Dehydrogenase RNA Expression in Jurkat 
Cells after 1% TSE Incubation. 
GAPDH expression levels were used as a positive control for qRT-PCR assay. 
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CHAPTER VI 
HIV INFECTIVITY DUE TO GENE KNOCKDOWN 
Jurkat siRNA Transfection 
Silencer Select pre-designed siRNAs (Ambion) targeting each of the 12 genes in 
question were used in transfection. Jurkat cells were diluted to a concentration of 5.0 x 
10
5
 cells/ml then 400ul of cells were added to wells of a 24 well cell culture plate (2.0 x 
10
5
 cells/well). Lipofectamine 2000 was used to transfect siRNA into cells. Transfection 
complexes were formed by adding 3ul of Lipofectamine 2000 to 47ul Opti-MEM I 
reduced serum media without serum. In a separate micro-centrifuge tube 10ul gene 
specific 0.5nM siRNA (final cell culture concentration = 10nM) was added to 40ul Opti-
MEM I reduced serum media without serum. These two 50ul samples were then added 
together and allowed to sit for 5 minutes at room temperature. Following the 5 minute 
incubation 100ul of transfection complex solution was added to Jurkat cells. Cells were 
then incubated at 37
o
C and 5% CO2 for 48 hours with new media exchanged at 24 hours 
post-transfection. Following incubation, cells were pelleted and stored at -80
o
C for RT-
PCR analysis or growth media was exchanged in preparation for HIV infectivity assay. 
qRT-PCR Analysis of Gene Knockdown 
Cell pellets obtained in siRNA transfection were thawed and total RNA isolation 
was performed using Sigma RNA isolation kit. RNA samples were then quantified and  
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all samples diluted to 100ng/ul. Total RNA samples (200ng) were run through one 
reverse transcriptase cycle using random hexamers in preparation for real time PCR 
analysis. qRT-PCR reaction was setup using manufactures recommendations. Sigma Sybr 
Green Jumpstart Taq was used along with appropriate primer set for each gene. The ∆∆Ct 
method was performed using the ABI 7500 Fast PCR system, and β-actin and GADPH as 
endogenous controls. Zero hour fluorescence reading was normalized to 1 on relative 
quantitation  scale. 
The qRT-PCR cycle used was as follows:  
 
 
95
o
C x 120secs 
95
o
C x 15secs 
55
o
C x 60secs          50x  
Fluorescence read     
 
 
HIV Infectivity as a Result of Gene Knockdown in Jurkat Cells 
Forty-eight hours post transfection of jurkat cells, media was removed from cells 
and replaced with RPMI 1640 growth media. Cells were then infected with HIV-1 
(MOI=0.1) and incubated at 37
o
C and 5% CO2 for 48 hours. After the 48 hour incubation 
period, the jurkat cells were then pelleted and 100ul culture supernatant was added to 1.2 
x 10
4
 cells/100ul TZM-bl cells plated in 96-well cell culture plate. The TZM-bl cells 
were incubated at 37
o
C and 5% CO2 for 48 hours. Following the TZM-bl cell incubation, 
the growth media was removed from the wells containing cells. Cells attached to plate 
surface were washed with 1x PBS solution two times, then 20ul of 1X luciferase cell 
culture lysis reagent (Promega) was added to each well. The plate was rocked to ensure 
complete coverage of cell layer in each well. The plate was then incubated at 37
o
C and 
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5%CO2 for 5 minutes. 100ul luciferase assay reagent was added to each well using multi-
channel pipet to reduce pipetting time. The plate was immediately placed inside the 
Biotek luminescence microplate reader, and luminescence measured in each well. 
TAX1BP1 
  
Chin et. al. found that Tax1 binding protein 1 (TAX1BP1) interacts with the 
oncoprotein Tax, a transcriptional regulator from the Human T-cell leukemia virus type 1 
(HTLV-1) [23].  They show that TAX1BP1 is a nuclear receptor coactivator that will 
colocalize with Tax to the nucleus, where it can bind to HTLV-1 long terminal repeat 
(LTR). The Viral LTR controls viral gene expression through the presence of enhancer, 
promoter, transcription initiation, and transcription termination sites. It is fair to say that 
if TAX1BP1 is overexpressed in cells treated by TSE, and that it can bind to the viral 
LTR, it may be possible that TAX1BP1 could have some role in activating HIV 
infectivity. 
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Figure 22. siRNA Induced TAX1 Binding Protein 1 mRNA Knockdown in Jurkat 
Cells. 
Left to Right:TAX1 Binding Protein 1 mRNA levels in Jurkat control cells (no siRNA), 
TAX1BP1 siRNA transfected cells, GADPH housekeeping gene mRNA levels in Jurkat 
control cells, and TAX1BP1 siRNA transfected cells.  
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Figure 23. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of TAX1 Binding Protein 1 Gene Expression Knockdown. 
Jurkat cells transfected with TAX1BP1 siRNA were infected with HIV, then cell 
supernatant was added to TZM-bl cells and luciferase activity measured 48 hours post 
supernatant addition. Luciferase activity indicates a 53.2% reduction (p<0.05, statistically 
significant) in HIV infectivity as a result of TAX1BP1 expression knockdown. 
 
CD59, Protectin 
 CD59 is a compliment regulatory glycoprotein that incorporates into the cellular 
membrane, and will bind C8 and C9, thus inhibiting the formation of the C5b-9 
membrane attack complex [24].  This protects cells containing CD59 in the membrane 
from autologous complement mediated destruction, or destruction originating from the 
same cell being destroyed.  If CD59 is overexpressed in cells exposed to TSE, then it 
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could be more readily incorporated into virus particles being made from the infected 
cells, which would in turn increase the infectivity of the viral infection. 
 
 
Figure 24. siRNA Induced CD59 mRNA Knockdown in Jurkat Cells. 
Left to Right:CD59 mRNA levels in Jurkat control cells (no siRNA), CD59 siRNA 
transfected cells, GADPH housekeeping gene mRNA levels in Jurkat control cells, and 
CD59 siRNA transfected cells.  
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Figure 25. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of CD59 Gene Expression Knockdown. 
Jurkat cells transfected with CD59 siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 65.9% reduction (p<0.05, statistically significant) 
in HIV infectivity as a result of CD59 expression knockdown. 
 
 
Coatomer Protein Complex β-2 
 Nef is a dimerization protein from HIV that has been shown to down regulate the 
expression of the CD4 cell surface receptors in HIV infected cells through a post-
translational mechanism that is not fully understood yet [25, 26].  Co-
immunoprecipitation assays as well as in vitro studies have shown that there is an 
interaction between Nef and Coatomer Protein Complex β-2 [27]. Coatomer Protein 
Complex β-2 is an essential component in the protein trafficking through the golgi [28] 
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and has also been detected in the endosomal fraction of cells [29].  Both of these areas 
happen to be sites were the CD4 ends up as a result of Nef induced down regulation [30]. 
This suggest that Coatomer Protein Complex β-2 might be one of the cellular mediators 
in the down regulation of CD4 by Nef, and that the up regulation of Coatomer Protein 
Complex β-2 as a result of exposure to TSE might play a role in the increased infectivity 
of HIV. 
 
 
Figure 26. siRNA Induced Coatomer Protein Complex β-2 mRNA Knockdown in 
Jurkat Cells. 
Left to Right: Coatomer Protein Complex β-2 mRNA levels in Jurkat control cells (no 
siRNA), CPCβ2 siRNA transfected cells, GADPH housekeeping gene mRNA levels in 
Jurkat control cells, and CPCβ2 siRNA transfected cells.  
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Figure 27. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Coatomer Protein Complex β 2 Gene Expression Knockdown. 
Jurkat cells transfected with CPCβ2 siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 24.8% reduction (p>0.05, not statistically 
significant) in HIV infectivity as a result of CPCβ2 expression knockdown. 
 
Thioredoxin-related Transmembrane Protein 1 
 Thioredoxin-related transmembrane protein 1 is a major component of clatherin-
associated adaptor protein complex that is involved in the clathrin-mediated endocytosis, 
and has been shown to be involved in the down regulation of CD4 and MHC class I 
molecules by the HIV protein Nef [31]. Just like Coatomer Protein Complex β-2, the up 
regulation of Thioredoxin-related transmembrane protein 1 due to the TSE may aid in the 
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increase in HIV infectivity due to an association with the down regulation of CD4 and 
MHC class I by the HIV protein Nef. 
 
 
 
Figure 28. siRNA Induced Thioredoxin-Related Transmembrane Protein 1 mRNA 
Knockdown in Jurkat Cells. 
Left to Right: Thioredoxin-related transmembrane protein 1 mRNA levels in Jurkat 
control cells (no siRNA), TRTP1 siRNA transfected cells, GADPH housekeeping gene 
mRNA levels in Jurkat control cells, and TRTP1 siRNA transfected cells.  
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Figure 29. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Thioredoxin-Related Transmembrane Protein 1 Gene Expression Knockdown. 
Jurkat cells transfected with TRTP1 siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 52.5% reduction (p<0.05, statistically significant) 
in HIV infectivity as a result of TRTP1 expression knockdown. 
 
 
Calmodulin 1 
 Upon HIV infection, there is eventually an accelerated loss of CD4+ T-
lymphocytes, which is a key factor in the progression of the disease.  One mechanism in 
this rapid loss of CD4+ T cells is through apoptosis [32].  Although not fully understood 
it is suggested that HIV related apoptosis is from the FAS pathway.  When FAS ligand 
binds FAS it recruits signaling molecules which activate caspase 3, which then activates 
caspase 6, and eventually DNA fragmentation factor resulting in cleavage of the DNA 
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[33]. The HIV glycoprotein gp160 contains two calmodulin binding sites on its c-
terminal end.  Expression of gp160 in Jurkat T cells results in increased sensitivity to 
FAS mediated apoptosis.  This increase in sensitivity is blocked in the presence of the 
two calmodulin antagonists tamoxoifen and trifluoperazine.  In addition, the mutation of 
the two calmodulin binding sites on gp160 eliminates the gp160 dependent FAS-
mediated apoptosis [34].  This indicates that the gp160 induced apoptosis seen in HIV 
infection of T cells is dependent on calmodulin up regulation, and binding to the c-
terminal domain of gp160.  This clearly demonstrates the need for the up regulation of 
calmodulin as seen with exposure to TSE in the increase in HIV infectivity. 
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Figure 30. siRNA Induced Calmodulin 1 mRNA Knockdown in Jurkat Cells. 
Left to Right: Calmodulin 1 mRNA levels in Jurkat control cells (no siRNA), Cal1 
siRNA transfected cells, GADPH housekeeping gene mRNA levels in Jurkat control 
cells, and Cal1 siRNA transfected cells.  
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Figure 31. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Calmodulin 1 Gene Expression Knockdown. 
Jurkat cells transfected with Cal1 siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 77.5% reduction (p<0.05, statistically significant) 
in HIV infectivity as a result of Cal1 expression knockdown. 
 
 
HSP90 β-1 
 Activation of HIV transcription requires the activity of human transcription 
elongation factor (P-TEFb) which then interacts with Tat and then phosphorylates the C-
terminal domain of RNA polymerase II.  It is believed that the Cdk9/cyclin T1 dimer is 
the active form of P-TEFb, which interacts with Tat [33].  Cdk9 is the catalytic subunit 
that eventually phosphorylates RNA polymerase II.  In order for Cdk9 to interact with 
cyclin T1 it must first bind with the kinase-specific chaperone complex Hsp90/Cdc37.  
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Upon inactivation of the Hsp90/Cdc37 complex by geldanamycin, there was a significant 
increase in the levels of Cdk9 unable to bind to cyclin T1.  Effectively breaking the chain 
which allowed for activation of RNA polymerase II [36].  This shows a need for the 
presence of Hsp90 in the HIV transcriptional activation cascade which indicates the 
importance of this  protein and possibly its up regulation by TSE in the increase in HIV 
infectivity. 
 
 
 
Figure 32. siRNA Induced Heat Shock Protein 90 β 1 mRNA Knockdown in Jurkat 
Cells. 
Left to Right: Heat shock protein 90 β 1 mRNA levels in Jurkat control cells (no siRNA), 
HSP90b1 siRNA transfected cells, GADPH housekeeping gene mRNA levels in Jurkat 
control cells, and HSP90b1 siRNA transfected cells.  
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Figure 33. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Heat Shock Protein 90 β-1 Gene Expression Knockdown. 
Jurkat cells transfected with HSP90b1 siRNA were infected with HIV, then cell 
supernatant was added to TZM-bl cells and luciferase activity measured 48 hours post 
supernatant addition. Luciferase activity indicates a 70.6% reduction (p<0.05, statistically 
significant) in HIV infectivity as a result of HSP90b1 expression knockdown. 
 
 
Sjogren Syndrome Antigen B 
 Sjogren Syndrome Antigen B, also known as La protein, is involved in RNA 
protection and metabolism. It has been shown to protect the 3’-UUU(OH) segments of 
newly RNA polymerase III transcribed RNA. It also acts as an RNA chaperone and binds 
to RNA’s from the Hepatitis C virus [37].  Since both HIV and Hepatitis C virus are both 
positive-sence RNA viruses, Sjogren Syndrome Antigen B may also play a role in the 
increase of HIV infectivity from TSE. 
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Figure 34. siRNA Induced Sjogren Syndrome Antigen B mRNA Knockdown in 
Jurkat Cells. 
Left to Right: Sjogren Syndrome Antigen B mRNA levels in Jurkat control cells (no 
siRNA), SSAB siRNA transfected cells, GADPH housekeeping gene mRNA levels in 
Jurkat control cells, and SSAB siRNA transfected cells.  
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Figure 35. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Sjogren Syndrome Antigen B Gene Expression Knockdown. 
Jurkat cells transfected with SSAB siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 35.3% reduction (p>0.05 not statistically 
significant) in HIV infectivity as a result of SSAB expression knockdown. 
 
 
DDX3 
 DEAD-box RNA helicases are involved in RNA transcription, translation, RNA 
splicing, RNA transport, and RNA degradation.  DDX3 is a DEAD-box RNA helicase 
that has been implicated in the replication of HIV.  DDX3 is a nucleo-cytoplasmic 
shuttling protein that will localize near the nuclear pores.  Knockdown of DDX3 
suppressed the export of HIV RNA’s to the cytoplasim causing inefficient viral 
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replication [38, 39]. The up regulation of DDX3 from TSE may also play a role in the 
increase of HIV infectivity. 
 
 
Figure 36. siRNA Induced DDX3 mRNA Knockdown in Jurkat Cells. 
Left to Right: DDX3 mRNA levels in Jurkat control cells (no siRNA), DDX3 siRNA 
transfected cells, GADPH housekeeping gene mRNA levels in Jurkat control cells, and 
DDX3 siRNA transfected cells.  
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Figure 37. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of DDX3 Gene Expression Knockdown. 
Jurkat cells transfected with DDX3 siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 56.0% reduction (p<0.05, statistically significant) 
in HIV infectivity as a result of DDX3 expression knockdown. 
 
 
Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) 
 
 Research has shown that overexpression of glutathione peroxidases (GPx) 
specifically PHGPx is sufficient to inhibit NF-B activation by IL-1 [40].  HIV 
transcription is dependent on host transcription factors like NF-B for activation. The 
HIV LTR contains NF-B binding sites needed for efficient HIV transcription.  The lack 
of NF-B in infected HIV T cells does not completely inhibit HIV transcription but in the 
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absence of TAT, the transcripts are prematurely terminated.  By down-regulating the 
expression of PHGPx in infected cells, it may allow more NF-B to be activated causing 
an increase in HIV infectivity. 
 
 
Figure 38. siRNA Induced PHGPx mRNA Knockdown in Jurkat Cells. 
Left to Right: PHGPx mRNA levels in Jurkat control cells (no siRNA), PHGPx siRNA 
transfected cells, GADPH housekeeping gene mRNA levels in Jurkat control cells, and 
PHGPx siRNA transfected cells.  
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Figure 39. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of PHGPx Gene Expression Knockdown. 
Jurkat cells transfected with PHGPx siRNA were infected with HIV, then cell 
supernatant was added to TZM-bl cells and luciferase activity measured 48 hours post 
supernatant addition. Luciferase activity indicates a 53.2% increase (p<0.05, statistically 
significant) in HIV infectivity as a result of PHGPx expression knockdown. 
 
 
MHC, HLA-E 
 MHC class I is the gene product of one of 6 human leukocyte antigen (HLA) 
genes (HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G).  Each gene product is 
slightly different in structure, but they have the same function, to present fragments of 
proteins on the cell surface in order to alert the immune system.  The HIV Nef protein has 
been shown to down regulate the expression of MHC class I molecules from HLA-A, and 
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HLA-B genes [41].  The MHC molecules from HLA-C and HLA-E then signal the 
natural killer (NK) cells to lyse those cells expressing small amounts of MHC.  By the 
down-regulation of MHC from the HLA-E gene, the cell is then better able to prevent 
recognition from the NK cells and can continue to produce HIV viral particles, thereby 
causing the HIV to be more infective. 
 
 
 
Figure 40. siRNA Induced Human Leukocyte Antigen E mRNA Knockdown in 
Jurkat Cells. 
Left to Right: Human Leukocyte Antigen E mRNA levels in Jurkat control cells (no 
siRNA), HLA-E siRNA transfected cells, GADPH housekeeping gene mRNA levels in 
Jurkat control cells, and HLA-E siRNA transfected cells.  
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Figure 41. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Human Leukocyte Antigen E Gene Expression Knockdown. 
Jurkat cells transfected with HLA-E siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 52.3% increase (p<0.05, statistically significant) 
in HIV infectivity as a result of HLA-E expression knockdown. 
 
 
Steroyl-CoA Desaturase 
 Steroyl-CoA Desaturase is a key enzyme in fatty acid metabolism. The absence or 
down regulation of Steroyl-CoA Desaturase causes a state of lipodystrophy [42]. 
Lipodystrophy is the partial or complete absence of adipose tissue caused by the inability 
of the body to completely metabolize fatty acids. This causes triglycerides to accumulate 
in the liver, heart, muscle, and other tissues [43].  In individuals infected with HIV, this 
0
10000
20000
30000
40000
50000
60000
Lu
ci
fe
ra
se
 A
ct
iv
it
y 
p
e
r 
w
e
ll 
HLA-E 
61 
 
ensures the infected cells have a steady supply of cholesterol for the newly forming 
virions. Nef will bind to cholesterol and deliver it to the cell membrane where the new 
virus particles are assembled. By down regulating the expression of Steroyl-CoA 
Desaturase it allows the HIV infected cells a more abundance of cholesterol, which may 
increase the infectivity of the virus. 
 
 
Figure 42. siRNA Induced Stearoyl-CoA Desaturase mRNA Knockdown in Jurkat 
Cells. 
Left to Right: Stearoyl-CoA Desaturase mRNA levels in Jurkat control cells (no siRNA), 
Ster-CoA D siRNA transfected cells, GADPH housekeeping gene mRNA levels in Jurkat 
control cells, and Ster-CoA D siRNA transfected cells.  
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Figure 43. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Steroyl-CoA Desaturase Gene Expression Knockdown. 
Jurkat cells transfected with Ster-CoA D siRNA were infected with HIV, then cell 
supernatant was added to TZM-bl cells and luciferase activity measured 48 hours post 
supernatant addition. Luciferase activity indicates a 3.0% increase (p>0.05 not 
statistically significant) in HIV infectivity as a result of Ster-CoA D expression 
knockdown. 
 
 
Thioredoxin Interacting Protein 
 Thioredoxin Interacting Protein is an inhibitor of the reduction ability of 
Thioredoxin, by interacting with the catalytic center of the reduced form of Thioredoxin 
[44]. The action of TSE down regulates the expression of Thioredoxin Interacting Protein 
which will increase the reducing activity of Thioredoxin. Significantly increased levels of 
Thioredoxin, is an indicator in patients infected with HIV.  Patients with high plasma 
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thioredoxin levels also tend to have lower overall CD4+ cell counts [45].  This indicates 
that by down-regulating the expression of Thioredoxin Interacting Protein the TSE is 
increasing the infectivity of the HIV by presenting it with a better environment to 
replicate in. 
 
 
Figure 44. siRNA Induced Thioredoxin Interacting Protein mRNA Knockdown in 
Jurkat Cells. 
Left to Right: Thioredoxin interacting protein 1 mRNA levels in Jurkat control cells (no 
siRNA), TIP siRNA transfected cells, GADPH housekeeping gene mRNA levels in 
Jurkat control cells, and TIP siRNA transfected cells.  
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Figure 45. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of Thioredoxin Interacting Protein Gene Expression Knockdown. 
Jurkat cells transfected with TIP siRNA were infected with HIV, then cell supernatant 
was added to TZM-bl cells and luciferase activity measured 48 hours post supernatant 
addition. Luciferase activity indicates a 42.4% increase (p>0.05 not statistically 
significant) in HIV infectivity as a result of TIP expression knockdown. 
 
 
Dual Knockdown of DDX3 and Thioredoxin-related Transmembrane 
Protein 1 
DDX3 is a RNA helicase which has been shown to act as a nucleo-cytoplasmic 
shuttling protein which localizes near the nuclear pores. When the expression of DDX3 is 
knocked down the result is suppressed export of HIV RNA’s to the cytoplasim [36, 37]. 
Thioredoxin-related transmembrane protein 1 has been shown to play a role in the HIV 
Nef protein mediated down regulation to CD4 and MHC class I proteins from the cell 
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surface. The down regulation of CD4 from the cell surface enhances the release of fully 
infectious HIV-1 virions thereby promoting HIV infectivity [46-49]. The down-
regulation of HLA MHC class I allows the HIV infected cell to evade the host immune 
response [50]. With DDX3 and TRTP1 being utilized by HIV in different pathways, and 
the up-regulation of both genes showing the possibility of enhancing HIV infectivity, 
these 2 genes were selected in order to create a dual-knockdown cell sample and then 
HIV infectivity measured using the luciferase assay. 
Jurkat cells were transfected with DDX3 and TRTP1 siRNA/Lipofectamine 2000 
complexes simultaneously according to previously outlined procedure. Forty-eight hours 
post-transfection a cell sample was used in qRT-PCR quantitation of DDX3 and TRTP1 
gene expression. A second cell sample was used to measure HIV infectivity using the 
previously used luciferase assay in TZM-bl cells. 
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Figure 46. siRNA Induced DDX3 and Thioredoxin-Related Transmembrane Protein 
1 mRNA Dual Knockdown in Jurkat Cells. 
Left to Right: DDX3 mRNA levels in Jurkat control cells (no siRNA), DDX3/TMX1 
siRNA transfected cells, Thioredoxin-related transmembrane protein 1 mRNA levels in 
Jurkat control cells, TRTP1 siRNA transfected cells, GADPH housekeeping gene mRNA 
levels in Jurkat control cells, and TRTP1 siRNA transfected cells.  
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Figure 47. TZM-bl Luciferase Activity Indicating HIV Infectivity Levels as a Result 
of DDX3 and Thioredoxin-Related Transmembrane Protein 1 Dual Gene 
Expression Knockdown. 
Jurkat cells transfected with DDX3 and TRTP1 siRNA were infected with HIV, then cell 
supernatant was added to TZM-bl cells and luciferase activity measured 48 hours post 
supernatant addition. Luciferase activity indicates a 55.4% decrease (p<0.05, statistically 
significant) in HIV infectivity as a result of DDX3 expression knockdown alone, and a 
52.2% decrease (p<0.05, statistically significant) in HIV infectivity as a result of TRTP1 
expression knockdown alone. When the expression of both DDX3 and TRTP1 have been 
decreased by siRNA, there is a 59.6% reduction in HIV infectivity. While the reduction 
in HIV infectivity as a result of knockdown in each gene individually is statistically 
significant, the reduction in infectivity as a result of the dual knockdown of DDX3 and 
TRTP1 is not statistically significant (p>0.05) in relation to the individual knockdown 
levels. 
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CHAPTER VII 
DISCUSSION 
 
 
 The HIV viral epidemic has impacted almost all nations on the planet, along with 
the prevalence of tobacco smoking, so determining if a link exists between the two 
should be of top priority. In the U.S., tobacco smoking prevalence among those infected 
with HIV is believed to be 50%-70%, and the rate in substance abusers is even higher at 
75%, compared to the general U.S. population who are HIV negative with a smoking rate 
of 20.8% [3, 51-52]. 
Very few studies have looked at a possible link between tobacco use and the 
effect on HIV infectivity in respect to non-nicotine tobacco constituents, primarily due to 
the shortened life expectancy of those living with HIV. With the recent developments of 
new anti-retroviral therapies, however, life expectancy has continued to rise. With the 
current continued use of these treatments in developing countries where the rate of HIV 
incidence is at its highest, the life expectancy of those living with HIV will also continue 
to rise. This introduces the need to evaluate and address other health concerns, like 
tobacco smoking, as a way to further extend life expectancy as well as increase the 
quality of life of those living with HIV/AIDS . This study has filled a void at the 
cellular/genetic level determining what genes are altered by tobacco constituents and how 
the gene expression patterns may affect the infectivity level of the HIV virus.  
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qRT-PCR analysis was used to confirm micro array results which indicate that 
there are eight genes whose expression is increased in the presence of a 1% TSE solution 
whose concentration mimics the plasma concentration levels seen in smokers. The results 
also indicate that there are four genes whose expression levels were decreased as a result 
of the TSE solution. It is important to note that these studies were performed in Jurkat T-
cells, as T-cells are the primary target of the HIV virus. Gene expression studies have 
been performed on other cell types which show differing expression patterns. Maunders 
et.al. exposed tracheobronchial epithelium cells to cigarette smoke for one hour and 
genetic expression patterns were measured [53]. Gumus et. al. looked at expression 
differences in oral leukoplakia cells [54], and Rock et. al. examined TSE induced gene 
expression differences in HIV infected microglial cells [55]. The patterns of gene 
expression due to tobacco smoke vary among cell type making the study of gene 
expression changes in T-cells that much more crucial. 
The changes in gene expression as a result of tobacco smoke, outlined in this 
research take a multi-pronged approach by examining the pathways in which they affect 
the infectivity of HIV. There are combinations of proteins which act within the same 
cellular pathways, for example, the down regulation of PHGPx and Thioredoxin 
Interacting protein. Both of which influence the NF-ĸB pathway. It has been widely 
shown that the HIV LTR contains NF-ĸB binding sites which are required for efficient 
transcription of HIV genes. NF-ĸB, a pleiotropic transcription factor, in its dormant state 
exists as a dimer bound by I-ĸB inhibitory proteins found in the cytoplasm. Upon cellular 
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stimulation, notably by the production of reactive oxygen species (ROS), I-ĸB becomes 
phosphorylated inducing ubiquitination and the subsequent degradation of the inhibitory 
protein. After the degradation of I-ĸB, NF-ĸB will relocate to the nucleus in order to 
activate transcription. PHGPx, a glutathione peroxidase, has been shown to inhibit the 
(oxidative) cytosolic activation of NF-ĸB. This in turn will inhibit HIV gene 
transcription. Thioredoxin Interacting Protein has been shown to bind the reduced form 
of Thioredoxin at the catalytic center, inhibiting its reduction potential [44]. Reduction in 
levels of Thioredoxin have been linked to the reduction of activated NF-ĸB. Taken 
together, the results reported here show that tobacco smoke induces the down regulation 
of both PHGPx, and Thioredoxin Interacting Protein in jurkat cells, which in turn will 
increase levels of activated NF-ĸB, which is beneficial in the transcription of HIV genes. 
Other tobacco-induced gene expression changes affect independent pathways, 
from protecting infected cells or HIV viral particles from the host’s immune responses, to 
enhancing vesicular trafficking within a viral infected cell. The gene expression changes 
shown here contribute in one way or another to the enhanced infectivity of HIV. 
In conclusion, the results presented in this research have exhibited a link between 
the non-nicotine induced increase in HIV infectivity and the gene expression changes in 
jurkat cells as a result of tobacco smoke. This work provides a solid base on which 
further studies can be built. The need for more in depth dual and triple knockdown cell 
lines will begin to delve into the extent in which these genes work together to enhance 
viral infectivity. They may also provide insight into cellular targets for which agonists 
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and/or antagonists can be designed to decrease the level of HIV infectivity to an accepted 
level in those living with the virus. In addition, the effect on infectivity of other viruses 
with similar cellular pathways can be examined when these genes are either over or under 
expressed. 
 
72 
 
REFERENCES 
1. Asma S, Pederson L. Tobacco control in Africa: opportunities for prevention. 
Tobacco Control 1999; 8: 353-354. 
 
2. Vlllth International Conference on AIDS, Abstract # 2114. Amsterdam. July, 
1992. 
 
3. Crothers, K., Griffith, T.A., McGinnis, K.A., Rodriguez-Barradas, M.C., Leaf, 
D.A., Weissman, S., Gibert, C.L., Butt, A.A., Justice, A.C. (2005) The impact of 
cigarette smoking on mortality, quality of life, and co-morbid illness among HIV-
positive veterans. J Gen Intern Med 20, 1142-5. 
 
4. Siraprapasiri, T., Foy H. M., Kreiss, J. K. Frequency and risk of HIV infection 
among men attending a clinic for STD in Chiang Mai, Thailand. Southeast Asian 
J Trop Med Public Health 1996; 27:96-101. 
 
5. Burns, D. N., Kramer, A., Frances, Y. Cigarette smoking: a modifier of human 
immunodeficiency virus type 1 infection? J AIDS 1991; 4:76-83. 
 
6. Webber P M, Schoenbaum E E, Gourevitch M N. et al A prospective study of 
HIV disease progression in female and male drug users. AIDS 1999. 13257–262. 
 
7. Stephenson J M, Griffioen A, Woronowski H. et al Survival and progression of 
HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Sex 
Transm Infect 1999. 75247–252 
 
8. Conley L J, Bush T J, Buchbinder S P. et al The association between cigarette 
smoking and selected HIV-related medical conditions. AIDS 1996. 101121–1126.  
 
9. Coates R A, Farewell V T, Raboud J. et al Cofactors of progression to acquired 
immunodeficiency syndrome in a cohort of male sexual contacts of men with 
human immunodeficiency virus disease. Am J Epidemiol 1990. 132717–722
73 
 
10. Burns D N, Hillman D, Neaton J D. et al Cigarette smoking, bacterial pneumonia, 
and other clinical outcomes in HIV-1 infection. J Acquir Immune Def Syndr Hum 
Retrovir 1996. 13374–383. 
 
11. Eskild A, Petersen G. Cigarette smoking and drinking alcohol are not associated 
with rapid progression to acquired immunodeficiency syndrome among 
homosexual men in Norway. Scand J Soc Med 1994. 3209–212.  
 
12. Galai N, Park L P, Wesch J. et al Effect of smoking on the clinical progression of 
HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997. 14451–
458. 
 
13. Craib K J P, Schechter M T, Montaner J S G. et al The effect of cigarette smoking 
on lymphocyte subsets and progression to AIDS in a cohort of homosexual men. 
Clin Invest Med 1992. 15301–308. 
 
14. Furber, A.S., Maheswaran, R., Newell, J.N., Carroll, C. (2007) Is smoking 
tobacco an independent risk factor for HIV infection and progression to AIDS? A 
systemic review. Sex Transm Infect 83, 41-46. 
 
15. D´Cruz, O.J.; Uckun, F.N. (2006), Dawn of non-nucleoside inhibitor-based anti-
HIV microbicides, Journal of Antimicrobial Chemotherapy 57 (3): 411–423. 
 
16. Feldman, J.G., Minkoff, H., Schneider, M.F., Gange, S.J., Cohen, M., Watts, 
D.H., Gandhi, M., Mocharnuk, R.S., Anastos, K. (2006) Association of cigarette 
smoking with HIV prognosis among women in the HAART era: a report from the 
women's interagency HIV study. Am J Public Health 96, 1060-5. 
 
17. Rai, M.R., K. N.; Gupta, V. K. (1994) spectrophotometric method for the 
determination of total tobacco alkaloids and nicotine. analyst 119, 1883-1885. 
 
18. Taylor, R.G., Woodman, G., Clarke, S.W. (1986) Plasma nicotine concentration 
and the white blood cell count in smokers. Thorax 41, 407-8. 
 
19. Hoffmann, D., Wynder, E.L. (1986) Chemical constituents and bioactivity of 
tobacco smoke. IARC Sci Publ, 145-65. 
74 
 
20. Rock, R.B., Gekker, G., Aravalli, R.N., Hu, S., Sheng, W.S., Peterson, P.K. 
(2008) Potentiation of HIV-1 expression in microglial cells by nicotine: 
involvement of trBraut-Boucher, F. et al. J. Immunol. Methods 178, 41 (1995). 
 
21.  Braut-Boucher, F. et al. J. Immunol. Methods 178, 41 (1995). 
 
22.  Akeson, AL. et al. J. Immunol. Methods 163, 181 (1993). 
 
23. Chin, K.T., Chun, A.C., Ching, Y.P., Jeang, K.T., Jin, D.Y. (2007) Human T-cell 
leukemia virus oncoprotein tax represses nuclear receptor-dependent transcription 
by targeting coactivator TAX1BP1. Cancer Res 67, 1072-81. 
 
24. Bohana-Kashtan, O., Ziporen, L., Donin, N., Kraus, S., Fishelson, Z. (2004) Cell 
signals transduced by complement. Mol Immunol 41, 583-97. 
 
25. Guy, B., KiBny, M. P., Riviere, Y., Le Peuch, C., Dott, K., Girard, M., 
Montagnier, L., and Lecocq, J. P. (1987) HIV F/3' orf encodes a phosphorylated 
GTP-binding protein resembling an oncogene product, Nature 330, 266-269. 
 
26. Garcia, J. V., and Miller, A. D. (1991) Serine phosphorylation-independent 
downregulation of cell-surface CD4 by nef, Nature 350, 508-510. 
 
27. Benichou, S., Bomsel, M., Bodeus, M., Durand, H., Doute, M., Letourneur, F., 
Camonis, J., Benarous, R. (1994) Physical interaction of the HIV-1 Nef protein 
with beta-COP, a component of non-clathrin-coated vesicles essential for 
membrane traffic. J Biol Chem 269, 30073-6. 
 
28. Pepperkok, R., Scheel, J., Horstmann, H., Hauri, H. P., Griffiths, G., and Kreis, T. 
E. (1993) β-COP is essential for biosynthetic membrane transport from the 
endoplasmic reticulum to the Golgi complex in vivo, Cell 74, 71-82. 
 
29. Mellman, I., Yamamoto, E., Whitney,J . A,, Kim, M., Hunziker, W., and Matter, 
K. (1993) J. Cell Sci. Suppl. 17,l-7. 
 
30. Aiken, C., KonnerJ, ., Landau, N. R., Lenburg, M. E., and Trono, D. (1994) Nef 
induces CD4 endocytosis: Requirement for a critical dileucine motif in the 
membrane-proximal CD4 cytoplasmic domain, Cell 76,853-864. 
75 
 
31. Toh, Q.C., Tan, T.L., Teo, W.Q., Ho, C.Y., Parida, S., Chen, W.N. (2005) 
Identification of cellular membrane proteins interacting with hepatitis B surface 
antigen using yeast splitubiquitin system. Int J Med Sci 2, 114-7. 
 
32. Zhang, Y. J., Fadeel, B., Hodara, V., and Fenyo, E. M. (1997) Induction of 
apoptosis by primary HIV-1 isolates correlates with productive infection in 
peripheral blood mononuclear cells, AIDS 11, 1219–1225. 
 
33. Ashkenazi, A., and Dixit, V. M. (1998) Death Receptors: Signaling and 
Modulation, Science 281, 1305–1308. 
 
34. Micoli, K.J., Pan, G., Wu, Y., Williams, J.P., Cook, W.J., McDonald, J.M. (2000) 
Requirement of calmodulin binding by HIV-1 gp160 for enhanced FAS-mediated 
apoptosis. J Biol Chem 275, 1233-40. 
 
35. Peng, J., Zhu, Y., Milton, J. T., and Price, D. H. (1998) Stimulation of Tat-
associated kinase-independent transcriptional elongation from the human 
immunodeficiency virus type-1 long terminal repeat by a cellular enhancer, Genes 
Dev. 12, 755–762. 
 
36. O'Keeffe, B., Fong, Y., Chen, D., Zhou, S., Zhou, Q. (2000) Requirement for a 
kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 
heterodimer responsible for P-TEFbmediated tat stimulation of HIV-1 
transcription. J Biol Chem 275, 279-87. 
 
37. Domitrovich, A.M., Diebel, K.W., Ali, N., Sarker, S., Siddiqui, A. (2005) Role of 
La autoantigen and polypyrimidine tract-binding protein in HCV replication. 
Virology 335, 72-86. 
 
38. Fang, J., S. Kubota, B. Yang, N. Zhou, H. Zang, R. Godbout, and R. J. 
Pomerantz. 2004. A DEAD box protein facilitates HIV-1 replication as a cellular 
co-factor of Rev. Virology 330:471–480. 
 
39. Yedavalli, V. S., C. Neuveut, Y. H. Chi, L. Kleiman, and K. T. Jeang. 2004. 
Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export 
function. Cell 119:381–392. 
 
76 
 
40. Brigelius-Flohe, R., Friedrichs, B., Maurer, S., Schultz, M., Streicher, R. (1997) 
Interleukin-1-induced nuclear factor kappa B activation is inhibited by 
overexpression of phospholipids hydroperoxide glutathione peroxidase in a 
human endothelial cell line. Biochem J 328, 199-203. 
 
41. Williams, M., Roeth, J.F., Kasper, M.R., Fleis, R.I., Przybycin, C.G., Collins, 
K.L. (2002) Direct binding of human immunodeficiency virus type 1 Nef to the 
major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts 
MHC-I trafficking. J Virol 76, 12173-84. 
 
42. Miyazaki, M., Kim, Y.C., Gray-Keller, M.P., Attie, A.D., Ntambi, J.M. (2000) 
The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in 
mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 
275, 30132-8. 
 
43. Cohen, P., Friedman, J. M. (2004) Leptin and the Control of Metabolism: Role for 
Stearoyl-CoA Desaturase-1 (SCD-1). J. Nutrition 134: 2455S-2463S. 
 
44. Maulik, N., Das, D.K. (2008) Emerging potential of thioredoxin and thioredoxin 
interacting proteins in various disease conditions. Biochim Biophys Acta 1780, 
1368-82. 
 
45. Nakamura, H., De Rosa, S., Roederer, M., Anderson, M.T., Dubs, J.G., Yodoi, J., 
Holmgren, A., Herzenberg, L.A., Herzenberg, L.A. (1996) Elevation of plasma 
thioredoxin levels in HIVinfected individuals. Int Immunol 8, 603-11. 
 
46. Ross TM, Oran AE, Cullen BR: Inhibition of HIV-1 progeny virion release by 
cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol 
1999, 9:613-621. 
 
47. Lundquist CA, Tobiume M, Zhou J, Unutmaz D, Aiken C: Nef-mediated 
downregulation of CD4 enhances human immunodeficiency virus type 1 
replication in primary T lymphocytes. J Virol 2002, 76(9):4625-4633. 
 
48. Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, : Ability of HIV-1 Nef 
to downregulate CD4 and HLA class I differs among viral subtypes. 
Retrovirology 2013, 100(10). 
77 
 
49. Argañaraz ER, Schindler M, Kirchhoff F, Cortes MJ, Lama J: Enhanced CD4 
downmodulation by late stage HIV-1 nef alleles is associated with increased Env 
incorporation and viral replication. J Biol Chem 2003, 278(36):33912-33919. 
 
50. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, 
Baltimore D: The selective downregulation of class I major histocompatibility 
complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 
1999, 10(6):661-671. 
 
51. Turner J, Page-Schafer K, Chin DP, Osmond D, Mossar M, Markstein L: Adverse 
impact of cigarette smoking on dimensions of health-related quality of life in 
persons with HIV infection. AIDS Patient Care and STDs. 2001;15(12):615–624. 
 
52. Miguez-Burbano MJ, Ashkin D, Rodriguez A: Increased risk of Pneumocystis 
carinii and community-acquired pneumonia with tobacco use in HIV disease. Int J 
Infect Dis. 2005;9(4):208–217. 
 
53. Maunders, H., Patwardhan, S., Phillips, J., Clack, A. and Richter, A.: Human 
bronchial epithelial cell transcriptome: gene expression changes following acute 
exposure to whole cigarette smoke in vitro. Am J Physiol Lung Cell Mol Physiol. 
2007; 292, L1248-1256. 
 
54. Gumus, Z.H., Du, B., Kacker, A., Boyle, J.O., Bocker, J.M., Mukherjee, P., 
Subbaramaiah, K., Dannenberg, A.J. and Weinstein, H.: Effects of tobacco smoke 
on gene expression and cellular pathways in a cellular model of oral leukoplakia. 
Cancer Prev Res 2008; 1,100-111. 
 
55. Rock, R.B., Gekker, G., Aravalli, R.N., Hu, S., Sheng, W.S. and Peterson, P.K.: 
Potentiation of HIV-1 expression in microglial cells by nicotine: involvement of 
transforming growth factor-beta 1. J Neuroimmune Pharmacol 2008; 3, 143-149. 
 
78 
 
APPENDIX A  
 
CELL MEDIA PREPARATION 
 
 
To make 500 mL of RPMI1640 Medium for Jurkat Cells 
Starting with RPMI 1640, 1X Medium w/o L- Gln, 
RPMI1640      435mL 
10% FBS(fetal Bovine Serum)   50 mL 
1% of 200 mM L-Glutamine    5 mL of 200 mM solution 
 
1. Remove a 50 mL aliquot of FBS from the freezer and thaw in warm water. 
2. Open a 500 mL bottle of fresh RPMI under sterile conditions 
3. Remove 65 mL of media. 
4. Add 5 mL of 200 mM L-glutamine from the -20 freezer 
5. Add 50 mL (56.8 mL) of FBS 
6. Mix well, label bottle with initials, date, contents, etc. 
7. The media need not be filtered unless any of the reagents are not sterile 
(everything we purchase is cell culture grade) 
8. Place 1 mL of newly prepared media in the incubator overnight to check sterility 
before storing cell, if it turns cloudy contamination has occurred. 
9. Media will last about 2 months in the refrigerator. 
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APPENDIX B 
 
PROCEDURE FOR COUNTING CELLS 
 
 
Procedure: 
1. Percuss the cells vigorously to dissociate the cells from each other. 
2. Open the cell flask and remove less than 100 μL of the media (fill the tip only). 
3. Place the sample in the centrifuge tube (if more than one flasks of cells is being 
counted be sure to label the tubes). 
4. Place 50 μL of trypan blue in the empty tube. 
5. To save plastic, reuse the pipette tip that was just used for the trypan blue and remove 
50 
μL of cells/media from the first bullet tube, being sure to mix the trypan blue and the 
cells 
well in the tube. (there is now a dilution factor of 2) 
6. Take the mixture in the tube to the microscope. 
7. Place a cover slip over the hemocytometer slide and insert 20 μL of the cell media/TB 
mixture in the small groove in-between the cover slip and the slide. 
8. Place slide on the microscope and bring into focus the grid and cells. 
9. Bring into focus the gridlines, use the 0.25 magnification which will narrow the 
sight to one field. Count a total of 4 different fields. 
10. Counting cells: 
A method is needed so that there is consistency to the count. If cells placement is on 
top of a gridline count only cells on left and upper gridline and ignore cells on 
bottom and right gridline or vise versa. Either way, be consistent. 
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Additionally, always move the slide in the same direction either clockwise or counter 
clockwise to count cells. Again, either way, be consistent. 
If there is difficulty focusing in on the gridline start with the lowest magnification 
(0.10) and graduate up in magnification power. 0.25 seems to work best. At this 
power one can see one field (4x4 squares) fully, making counting easy. 
The number between squares would be within 5% if the cells are evenly distributed. 
Keep an eye out for dead cells (dark blue) if there are numerous dead cells it is time 
to start troubleshooting. 
11. Using the counter, count number of cells in each 4x4 grid being sure to count all 
four of the 4x4 fields. 
12. Take the total number of cells counted, and calculate the total number of cells in 
culture: 
(total # of cells counted/4) x 2 (dilution factor) x 10
4
 cells/mL 
 
Cell senescence is characterized by changes in morphology and decreased growth 
rate. 
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APPENDIX C 
 
FREEZING CELLS 
 
 
1. Spilt cells into a T-75 in 15 mL of media and grow until cell count is 8 x 10
5
 or 9 x 
10
5
cells/mL. 
2. Prepare media with 10% DMSO + 90% FBS. 
3. Calculate the number of cryovials (externally threaded) that will be needed to freeze 
cells. Each cryovial should hold 2 x 10
6
 cells 
CALCULATION: (vol. media in T-75) x cell count (cells/mL) = # cells 
# cells/2 x 10
6
 = # vials needed 
4. Cryovials should be sterile and endotoxin free or autoclaved with drying to destroy 
endotoxin. 
5. Prepare the appropriate amount of STERILE freezing medium to have 1 mL per 
cryovial. 
The freezing medium is 7.5% DMSO in complete RPMI (with FBS) or the alternative 
mentioned above. 
CALCULATION: # tubes x 1mL/tube = mL of media needed. 
6. Keep media at 4° C (on ice) during procedure. 
7. Fill cryocontainer with 100% isopropanol and be sure it is already cooled. 
8. While medium is warming, label the cryotubes with the cell type, generation, cell 
number, date, your initials. Place clear tape over the labels to be sure that they don’t get 
washed off in the liquid N2. 
9. Be sure all supplies are ready and that all labeled tubes are under hood with caps off 
and 
ready to have cells added to them before putting cells in freezing medium (this is 
necessary because DMSO is toxic to cells and should only be combined with cells for the 
minimum amount of time). 
10. Spin cells in Falcon tube at 1500 rpm for 5 min. (check to be sure pellet has formed) 
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11. Discard supernatant from cells and add the appropriate volume of freezing medium 
(calculated in step 5) 
12. Pipet gently up and down to resuspend cells. 
13. Aliquot 1 mL of cell mixture into each cryotube, replace lids. 
14. Place in -20° C for 2 hours. 
15. Move the vials to -80° C freezer and allow them to cool overnight. 
16. Move cells from cryostorage device to liquid nitrogen in 4 -5 hr (although cells can 
survive up to 5 weeks at -80° C, better results are had with a shorter time). 
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APPENDIX D 
 
THAWING CELLS 
 
 
Note: Vials that have been stored in liquid N2 can explode on warming if the vials are 
leaky. For this reason it is wise to wear face protection and gloves. 
Be sure to test media for bacterial contamination by placing 5 mL in incubator for 24 hr. 
Procedure 
1. Turn on water batch to 37° C. 
2. Prepare one T25 flask and one 15 mL falcon tube with 5 mL media each. 
3. Remove cell vial from liquid N2. Check that cap is securely fastened. Transfer 
immediately to 37° C water bath. 
4. Swirl gently (bottom half only) in bath until barely thawed. Ensure lid is not 
submerged under surface of water bath. Be sure you have recovered any information 
recorded on the vial. 
5. Submerge vial in beaker of ETOH before placing vial under hood (water bath is a 
major 
source of contamination). Be sure the cap is on tight. Change your gloves. 
6. Under sterile hood, suck cells up in 1 mL pipette and transfer to falcon tube with 5 mL 
media already present. Rinse pipette up and down to facilitate complete transfer. 
7. OR: Transfer cells immediately into 15 mL of media in T-25 flask place in incubator 
for 
24 hr and then go to step 8. 
8. Spin @1500 rpm (no more than 800 rcf) for 5 min, should see pellet of cells (if media 
is 
cloudy, spin longer). 
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9. Remove media and discard. 
10. Add < 5 mL of media, gently rinse up and down in pipette to resuspend pellet. (If the 
cells have been frozen for a long period of time (decreased cell viability) best to suspend 
the cells in a smaller volume of media. You can always add more media in 24 – 48 hr) 
11. Gently transfer into a T-25 falcon flask 
12. Label the flask with the date, the cell type, and your initials. 
13. Place in CO2 incubator at 37.0 ºC, 5.0% CO2, 72% relative humidity. 
14. Check cell count every 24 – 48 hours 
15. After 20 passages, cells should be discarded. 
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APPENDIX E 
 
GENELUTE DIRECT MRNA ISOLATION 
 
 
Preparation Instructions 
Before beginning the procedure, do the following: 
 
1. Thoroughly mix reagents. Examine for precipitation. If any reagent forms a 
precipitate, warm at 55-65°C until the precipitate dissolves and allow to cool to 
room temperature before use. 
2. Dissolve the proteinase K in the 40% glycerol. Use 0.5ml of 40% glycerol for 5 
mg proteinase K (10 prep package) or 2.5 ml of 40% glycerol for 25mg proteinase 
K (70 prep package). Let sit at room temperature for a few minutes, and mix 
thoroughly before use. This product is stable at room temperature in its dry form, 
but store the proteinase K solution at 2-8°C.  
3. Add the proteinase K solution to a sufficient volume of Lysis Solution for that 
day’s use. The amount of Lysis Solution containing proteinase K required per 
preparation is 0.5 ml for cultured cells and 1.0 ml for tissue. Add 20μl of 
proteinase K solution per ml of Lysis Solution and mix thoroughly.  
4. Transfer approximately 120μl of Elution Solution per preparation into a 
microcentrifuge tube and heat to 65°C in a heating block.  
5. Ensure that the oligo(dT) beads are at room temperature and vortex thoroughly 
before use. 
 
Procedure 
 
1. Harvest cells or prepare tissue. For best yields of intact RNA, use only rapidly 
growing cells before they reach their maximum density or harvest tissue 
immediately from a freshly sacrificed animal. 
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a. Suspension cell cultures: Count cells. Pellet up to 107cells for 5minutes at 
300xg.  
Remove the culture medium completely and discard. Continue with step 2. 
b. Attached cell cultures: Release attached cells with trypsin and pellet before lysis. 
To release cells with trypsin, see the protocol under Trypsin in the technical 
information within the Tissue Culture section of the Sigma Catalog. Count cells. 
Pellet up to 107cells and proceed as for suspension cultures. 
c. Mammalian tissue: Quickly slice and weigh a piece of fresh or frozen tissue. Use 
10 to 40mg per preparation. Transfer to an appropriate vessel for homogenization 
and continue with step 2. Note: Tissue may be flash-frozen in liquid nitrogen and 
stored at –70°C for several months before preparing RNA. However, do not allow 
frozen tissue to thaw before disruption in Lysis Solution. 
2. Lyse and homogenize cells/tissue. This is a critical step that must be 
accomplished quickly and thoroughly. 
a. Pelleted cells: Vortex the pellet to loosen the cells. Add 0.5 ml Lysis Solution 
containing proteinase K. Vortex or pipette thoroughly until all clumps disappear. 
Transfer the lysed cells into a GenElute filtration column (blue insert with a 2ml 
receiving tube) and spin for 2 minutes. Discard the blue filtration column, and 
continue to step 3 with the homogenized lysate (flow-through liquid). 
b. Mammalian tissue: Add 1 ml of Lysis Solution containing proteinase K and 
homogenize immediately until no visible pieces remain. Continue with step 3. 
3. Digest with proteinase K. Incubate homogenized lysate at 65°C for 10 minutes 
to degrade nucleases and other proteins. After incubation, remove the tube(s) 
from the heating block, and proceed with steps 4 and 5.  
4. Prepare mRNA for binding. Add 32μl of the 5M NaCl solution to the digested 
cell lysate, or 64μl of 5 M NaCl to the digested tissue lysate. Note that the sodium 
chloride and oligo(dT) beads (step 5) may be added while the lysate is still warm. 
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5. Bind mRNA to oligo(dT) beads. Mix the oligo (dT) beads thoroughly by 
vortexing and inverting until resuspended and homogenous. Add 25μl of the 
resuspended oligo(dT) beads to the lysate-NaCl mixture, cap tube, and mix 
thoroughly by vortexing. Incubate the lysate/bead mixture at room temperature 
for 10 minutes. No mixing or rocking is necessary. During this incubation, the 
poly(A) tails of mRNA will hybridize with the oligo(dT) on the beads.  
6. Collect beads: mRNA complex. Pellet the oligo(dT) beads: mRNA complex by 
centrifuging for 5 minutes at maximum speed. Carefully remove and discard the 
supernatant, leaving behind approximately 50μl to avoid disturbing the pellet.  
7. Release and rebind mRNA (optional). For a more highly enriched mRNA 
preparation, bound material may be released from the beads into fresh lysis 
solution; mRNA is then rebound to the same beads. Add 0.5ml of Lysis Solution 
and 32μl of 5 M NaCl solution. Vortex thoroughly to resuspend the pellet. A 
series of short bursts on a vortex mixer are usually more effective than one long 
burst. Invert tube and inspect to verify complete release of pellet. Incubate 
suspension at 65°C for 5 minutes. Remove from heat and incubate at room 
temperature for 5 minutes. Repellet the bead: mRNA complex for 2 minutes. 
Remove and discard all but ~50μl of the supernatant as above. Note: This step 
may be omitted if rRNA contamination is not a concern, or if purification will be 
repeated as described in the note at the end of the procedure. 
8. First wash. Resuspend the pellet in 350μl of Wash Solution by vortexing or 
pipetting. A series of short bursts on a vortex mixer will help release the pellet. 
Transfer the suspension into a GenElute spin filter-collection tube assembly by 
pipetting. Make sure that all suspension is expelled from the pipette tip and that 
the pellet is completely removed from tube. Spin for 1-2 minutes at maximum 
speed. Discard the flow-through liquid, but retain the collection tube. 
9. Second wash. Pipette 350μl of Low Salt Wash Solution into the column. Spin for 
1-2 minutes. Discard the flow-through liquid, but retain the collection tube. 
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10. Third wash .Pipette another 350μl of Low Salt Wash Solution into the column. 
Spin for 1-2 minutes. 
11. First elution. Transfer the spin filter into a fresh collection tube. Discard the 
flow-through liquid and the original collection tube. Pipette 50μl of preheated 
Elution Solution (65°C) onto the spin filter ensuring that it contacts the bead: 
mRNA complex. Incubate for 2-5 minutes at 65°C. Spin for 1-2 minutes. Save the 
flow- through liquid; it contains most of the purified mRNA. 
12. Second elution. To maximize recovery of mRNA, pipette an additional 50μl of 
preheated Elution Solution (65°C) onto the bead: mRNA complex. Incubate for 2-
5 minutes at 65°C. Spin for 1-2 minutes. The poly(A)+mRNA is now in the flow-
through eluate (90-100μl total), and is ready for immediate use or storage at–
70°C. Keep the mRNA on ice whenever it is thawed for use. Note: If a highly 
enriched preparation is desired, repurify the mRNA by adding 400μl of Lysis 
Solution, 32μl of 5 M NaCl solution, and a fresh 25μl aliquot of oligo(dT) beads 
to the 100μl eluted mRNA. Vortex and incubate 10 minutes at room temperature. 
Pellet the beads for 2minutes, then wash and elute as in steps 8 through 12 above. 
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APPENDIX F  
 
SYBR GREEN JUMPSTART TAQ POLYMERASE 
 
 
Optimizing Primer Concentrations 
1. Prepare and dispense diluted primers (Fig 1). 
a.    Prepare 60 µL of 8 µM working solutions of both forward (fwd) and reverse 
(rev) primers in the first tubes of 2 separate 8-tube strips. 
b.    Dispense 30 µL of water into tubes 2-5. 
c.    Transfer 30 µL of the 8 µM primer solution from tube 1 into tube 2. Mix 
thoroughly by pipetting up and down at least 5 times. 
d.    Repeat transfer and mixing from tube 2 to 3, 3 to 4, and 4 to 5. 
e.    Using a multichannel pipettor, transfer 5 µL from the strip-tubes containing 
diluted fwd primer into the first 5 wells down columns 1-5 of a 96-well PCR 
plate. After adding fwd primer, PCR mix and template, final concentrations of 
fwd primer will be 1000, 500, 250, 125, 62.5 nM. 
f.    Similarly transfer 5 µL from the strip-tubes containing diluted rev primer into 
the first 5 wells across rows A-E. After adding PCR mix and template, final 
concentrations of rev primer will be 1000, 500, 250, 125 and 62.5 nM 
2. Prepare qPCR master mix: 
Add reagents below in an appropriate sized DNase-free tube. Mix gently by 
vortexing and briefly centrifuge to collect all components at the bottom of the 
tube. 
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Volume Reagent Final Concentration 
520 µL 2x SYBR Green JumpStart 
Taq ReadyMix 
1.25 units Taq DNA 
polymerase, 
10 mM Tris-HCl, 50 mM 
KCl, 3.5 mM MgCl2, 
0.2 mM dNTP, stabilizers 
(7 µL) Rox Reference Dye 1x 
q.s. to 676 µL Water   
676 µL Total Volume   
3. Aliquot 26 µL master mix into all wells in the PCR plate that contain primers 
(A1-E5) 
4. Mix Thoroughly and transfer 18 µL from each of wells A1 through E5 to wells 
A8 through E12. 
5. Add 2 µL template DNA (10-50 ng genomic DNA or 0.1-1 ng plasmid) to one set 
of reactions (columns 1-5) and 2 µL of water to the other columns (8-12). 
6. Mix gently by vortexing and briefly centrifuge to collect all components at the 
bottom of the tube. 
7. Perform Thermal cycling: 
 
Typical cycling parameters for 100 bp – 600 bp fragments: 
Initial Denaturation 95 °C 2 min 
50 cycles:   
     Denaturation 95 °C 
15 
sec 
     Annealing, extension, and read 
fluorescence 
55 °C or 5°C below lowest primer 
TM 
1 min 
Fluorescent Read 
 
8. Evaluate fluorescence plots (DRn) for reactions containing target nucleic acid 
(columns 1-5).  Primer combinations with the lowest Ct and the highest 
fluorescence will give the most sensitive and reproducible assays. 
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B. Procedure for Routine Analysis 
1. Preparation of a reaction master mix is highly recommended to give best 
reproducibility. Mix all reagents but template in a common mix, using ~10% 
more than needed. Once template is diluted into the reaction vessel, master mix is 
aliquoted into the proper tube or plate for thermocycling. 
Volume* Reagent Final Concentration 
25 µL 2 x JumpStart Taq 
ReadyMix 
1.25 units Taq DNA polymerase, 10 mM Tris-HCl, 50 
mM KCl, 3.5 mM MgCl2, 0.2 mM dNTP, stabilizers 
0.5 µL Rox Reference 
Dye 
1 x 
0.5mM Forward Primer Optimal Conc. from Sec. A 
0.5mM Reverse Primer Optimal Conc. from Sec. A 
1.0µL Template DNA 100 ng 
q.s. to 50 
µL 
Water   
50 µL Total Volume   
* Volume for 50 mL reaction, however component volumes may be scaled to give the 
desired reaction volumes. 
Mix gently by vortexing and briefly centrifuge to collect all components at the bottom of 
the tube. 
2. Perform Thermal cycling 
 
Typical cycling parameters for 100 bp – 600 bp fragments: 
Inital Denaturation 95 °C 2 min 
50 cycles: 
 
     Denaturation 95 °C 15 sec 
     Annealing, extension, and read fluorescence 55 
o
C 1 min 
Fluorescent Read  
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APPENDIX G 
 
LUCIFERASE ASSAY 
 
 
Protocol for Preparing Cell Lysates 
1. Add 4 volumes of water to 1 volume of 5X lysis buffer. Equilibrate 1X lysis buffer to 
room temperature before use. 
2. Carefully remove the growth medium from cells to be assayed. Rinse cells with PBS, 
being careful to not dislodge attached cells. Remove as much of the PBS rinse as 
possible. 
3. Add enough 1X Cell Culture Lysis Reagent buffer (CCLR) to cover the cells 
(e.g.,400μl/60mm culture dish, 900μl/100mm culture dish or 20μl per well of a 96-well 
plate). 4. 4. Rock 96-well plate several times to ensure complete coverage of the cells 
with lysis buffer.  
5. Store the supernatant/cell lysate at –70°C or proceed to Section 4. 
Protocol for Plate-Reading Luminometers 
1. Program the luminometer for the appropriate delay and measurement times (1 second 
delay, and 1 second measurement) 
2. Add 100uL of Luciferase Assay Reagent to each well. 
3. Place the plate, containing cell lysate and Luciferase Assay Reagent per well, into the 
luminometer. The well is read, then the plate is advanced to the next well for a repeat of 
the delay-read process. 
4. Measure the light produced for a period of 10 seconds. The light intensity of the 
reaction is nearly constant for about 1 minute and then decays slowly, with a half-life of 
approximately 10 minutes. The typical delay time is 2 seconds, and the typical read time 
is 10 seconds. The assay time may be shortened significantly to decrease the total read 
time if sufficient light is 
produced. For example, the total read time for all samples in a 96-well plate can be less 
than 5 minutes. 
